After a slow start, the race is on to inhibit key proteins and pathways within the complement system -- a biological cascade that is central to the innate immune system and many different diseases ...

Activation of the complement system through the alternative pathway is necessary for the development of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in animal models C5a ...

The classical pathway is triggered by antigen-antibody complexes and includes participation of all complement proteins C1 through C9. The classical pathway is initiated by the binding of C1q to ...

The classical pathway is initiated by binding of C1q to the pathogen surface, or binding of C1q to antibody/ antigen complexes, forming a link between innate and adaptive immunity.

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...

The complement system can be activated by the classical, lectin and alternative pathways. The lectin pathway is activated by binding of mannose-binding lectin (MBL), ficolins or collectins to ...

DNTH103 is a selective inhibitor of the active C1s protein in the complement system's classical pathway. Classical pathway activity is implicated in driving morbidity in a range of autoimmune ...

Stuart N. Isaacs, Girish J. Kotwal, Bernard Moss, Immunology, Complement Binding Protein, Vaccinia Virus Complement-Control Protein Prevents Antibody-Dependent Complement-Enhanced Neutralization of ...

RLS-0071 is a 15 amino acid peptide that both inhibits humoral inflammation by blocking classical pathway complement activation and cellular inflammation by blocking the neutrophil effectors ...

Researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) produced following COVID-19 vaccination.

“After more than a decade of groundbreaking research targeting the early classical complement pathway, we are excited to have reached an important step in the clinical development of ANX1502 ...